Avanir Pharmaceuticals to Participate in Two Conferences in August - WDRB 41 Louisville News

Avanir Pharmaceuticals to Participate in Two Conferences in August

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Avanir Pharmaceuticals, Inc.

ALISO VIEJO, Calif., Aug. 5, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in August.

  • Wedbush Life Sciences Conference
    • Presentation date: Tuesday August 12, 2014
    • Presentation time: 9:45 a.m. ET
  • Canaccord Genuity Annual Growth Conference
    • Presentation date: Wednesday, August 13, 2014
    • Presentation time: 3:00 p.m. ET

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Avanir Pharmaceuticals, Inc.

Logo - http://photos.prnewswire.com/prnh/20130207/LA55901LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WDRB. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.